These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 38420497

  • 1. Real-world effectiveness of erenumab in Japanese patients with migraine.
    Suzuki K, Suzuki S, Shiina T, Haruyama Y, Kobayashi S, Shioda M, Hirata K.
    Heliyon; 2024 Feb 29; 10(4):e26568. PubMed ID: 38420497
    [Abstract] [Full Text] [Related]

  • 2. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH, Lange KS, Fitzek MP, Siebert A, Steinicke M, Triller P, Hong JB, Reuter U, Raffaelli B.
    Front Neurol; 2023 Feb 29; 14():1154420. PubMed ID: 37034092
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, Hirata K.
    Cephalalgia; 2023 May 29; 43(5):3331024231177649. PubMed ID: 37231663
    [Abstract] [Full Text] [Related]

  • 4. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.
    J Headache Pain; 2022 Sep 17; 23(1):123. PubMed ID: 36115947
    [Abstract] [Full Text] [Related]

  • 5. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct 17; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 6. Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine.
    de Dios A, Pagès-Puigdemont N, Ojeda S, Riera P, Pelegrín R, Morollon N, Belvís R, Real J, Masip M.
    Headache; 2024 Sep 13. PubMed ID: 39268992
    [Abstract] [Full Text] [Related]

  • 7. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, Raffaelli B, Reuter U, Neeb L.
    Cephalalgia; 2022 Apr 13; 42(4-5):291-301. PubMed ID: 34644203
    [Abstract] [Full Text] [Related]

  • 8. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.
    Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R, Lambru G.
    J Headache Pain; 2022 Nov 04; 23(1):139. PubMed ID: 36333710
    [Abstract] [Full Text] [Related]

  • 9. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
    Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A, Reuter U, Raffaelli B.
    J Headache Pain; 2023 Oct 30; 24(1):144. PubMed ID: 37899428
    [Abstract] [Full Text] [Related]

  • 10. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.
    Headache; 2020 Oct 30; 60(9):2014-2025. PubMed ID: 32920850
    [Abstract] [Full Text] [Related]

  • 11. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F.
    Headache; 2021 Feb 30; 61(2):363-372. PubMed ID: 33337544
    [Abstract] [Full Text] [Related]

  • 12. Erenumab for episodic migraine prophylaxis.
    Overeem LH, Neeb L, Reuter U.
    Expert Rev Neurother; 2019 Aug 30; 19(8):751-757. PubMed ID: 30614741
    [Abstract] [Full Text] [Related]

  • 13. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A.
    BMC Neurol; 2022 Jun 16; 22(1):221. PubMed ID: 35710354
    [Abstract] [Full Text] [Related]

  • 14. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM.
    Front Neurol; 2021 Jun 16; 12():788159. PubMed ID: 35069416
    [Abstract] [Full Text] [Related]

  • 15. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
    Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S, ERT; for the Italian Migraine Registry study group.
    J Neurol; 2024 May 16; 271(5):2434-2443. PubMed ID: 38231271
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW, Blumenfeld AM, Halker Singh RB, Williams R, Zhang F, Chen PW, Hsu CP, Peng C, Snellman J, Chehrenama M, Ailani J.
    Headache; 2023 Feb 16; 63(2):233-242. PubMed ID: 36226464
    [Abstract] [Full Text] [Related]

  • 19. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d'Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C.
    J Headache Pain; 2021 Dec 18; 22(1):154. PubMed ID: 34922444
    [Abstract] [Full Text] [Related]

  • 20. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
    Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, Gusatovic J, Snellman J, Lopez-Lopez C, Ashina H, Amin FM.
    J Headache Pain; 2022 Jun 02; 23(1):61. PubMed ID: 35655137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.